All In Biotech

Drug Trial Radar · NCT04718961

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

A Phase 2a/2b Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in Adult Women With Intrahepatic Cholestasis of Pregnancy and Elevated Serum Bile Acid Concentrations (OHANA).

Last checked: Nov 19, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

4

Actual

Start

Jan 4, 2021

Primary completion

Dec 7, 2022

Study completion Dec 7, 2022

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1 is an open-label randomized study of volixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability of two doses of volixibat. Part 2 is a double-blind, placebo controlled, study designed to evaluate the safety and efficacy of a selected volixibat dose.

Conditions

  • Intrahepatic Cholestasis of Pregnancy

Interventions

  • VolixibatDrug

    Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.

  • PlaceboDrug

    Capsules matched to study drug minus active substance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the Safety and Tolerability of Volixibat in Participants With ICPTime frame: Through to end of treatment, up to 21 weeks

Locations

20 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Yale School of Medicine

    New Haven, Connecticut

  • University of Miami

    Miami, Florida

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • The University of Texas Medical Branch - Galveston

    Galveston, Texas

  • University of Texas Health Science Center

    Houston, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Christchurch Women's Hospital

    Christchurch, New Zealand

  • Capital & Coast District Health Board, Wellington Regional Hospital

    Wellington, New Zealand

  • Dunedin Hospital

    Dunedin, Otago, New Zealand

  • Birmingham Womens and Childrens NHS Foundation Trust

    Birmingham, United Kingdom

  • University Hospital of Wales

    Cardiff, United Kingdom

  • St Richard's Hospital

    Chichester, United Kingdom

  • Barts Health NHS Trust- Whipps Cross University Hospital

    London, United Kingdom

  • Royal Free London Hospital NHS Foundation Trust

    London, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom

  • West Middlesex University Hospital

    Middlesex, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

  • Medway NHS Foundation Trust

    Gillingham, Kent, United Kingdom

  • Bradford Royal Infirmary

    Bradford, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.